Practical Strategies for Monitoring and Managing Toxicities With Novel Therapies for HER2-Positive Gastroesophageal Adenocarcinoma

Activity Overview

The management of esophagogastric adenocarcinoma has evolved substantially with the introduction of effective targeted and immunologic therapies. However, these therapies are appropriate mainly for patients with specific biomarkers, necessitating careful coordination among the multidisciplinary team to ensure proper tissue stewardship and testing, which, in turn, allows for appropriate treatment selection and sequencing, as well as the management and mitigation of adverse events.

In this webcast, experts in the management of esophagogastric adenocarcinoma discuss the management of adverse events associated with different options along the treatment continuum for human epidermal growth factor receptor 2 (HER2)–positive disease. These points are discussed in the context of patient case scenarios that highlight challenges in the management of HER2-positive esophagogastric cancers.

This educational activity is an archive of the live virtual symposium held on June 15, 2026.

Target Audience

This educational program is primarily directed toward medical oncologists, molecular pathologists, radiologists, gastroenterologists, advanced practice providers, and nurses who are involved in the management of patients with advanced or metastatic gastroesophageal adenocarcinomas.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Implement strategies to mitigate and manage adverse events associated with HER2-targeted therapy
• Enhance coordination among oncology care teams to support informed decision-making, treatment access, and patient engagement when managing HER2-positive gastroesophageal adenocarcinoma

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

PER^® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Additional Disclaimers

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.

This accredited activity has been developed in accordance with applicable accreditation standards to ensure balance, independence, objectivity, and scientific rigor. Faculty were instructed to use generic names where possible and to base recommendations on the best available evidence.

In the context of clinical discussion, proprietary product names may be mentioned. Such references are made for educational purposes only and do not constitute endorsement of any commercial product or service.

Learners are encouraged to independently evaluate the information presented and apply their own clinical judgment when considering patient care decisions.